By screening 100 active or dominant-negative mutants resulting in persistent activation of cancer-associated signaling nodes in a BAP1 wild-type UVM model (92.1) and validating the top hits in a BAP1-mutated cellular model (MP46), we characterized potential signaling mechanisms that modulate sensitivity to GNAQ-pathway inhibition. Here, BAP1 is linked to cancer.